CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
136-150 of 1187
IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
CME/CEIBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
Simple Diagnostic Steps That Change TD Outcomes & Increase Quality of Life
CME/CESimple Diagnostic Steps That Change TD Outcomes & Increase Quality of Life
Extra Innings – Sustaining Victory Beyond the First Game
MinuteCE®Extra Innings – Sustaining Victory Beyond the First Game
Swing for the Fences – LDL-C as the Power Hitter
MinuteCE®Swing for the Fences – LDL-C as the Power Hitter
Small Ball Wins Games – Combination Therapy for Goal Attainment
MinuteCE®Small Ball Wins Games – Combination Therapy for Goal Attainment
- advertisement
Crossing Home Plate – Building a Winning Team Culture
MinuteCE®Crossing Home Plate – Building a Winning Team Culture
Turning the Double Play – Comprehensive Secondary Prevention
MinuteCE®Turning the Double Play – Comprehensive Secondary Prevention
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®Ongoing Trials in Oral Targeted Strategies in Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
- advertisement
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
CME/CE Broadcast ReplayA Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and HematologyDESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease





















































